{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:34:02Z","timestamp":1791473642309,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79024-8","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:13:22Z","timestamp":1732079602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum protein and imaging biomarkers after intermittent steroid treatment in muscular dystrophy"],"prefix":"10.1038","volume":"14","author":[{"given":"Alexander B.","family":"Willis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Zelikovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sufit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senda","family":"Ajroud-Driss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Vandenborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis R.","family":"Demonbreun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinandan","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"79024_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, Part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77\u201393 (2010).","journal-title":"Lancet Neurol."},{"key":"79024_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","volume":"41","author":"GM Fenichel","year":"1991","unstructured":"Fenichel, G. M. et al. Long-term benefit from prednisone therapy in duchenne muscular dystrophy. Neurology 41, 1874\u20131877 (1991).","journal-title":"Neurology"},{"key":"79024_CR3","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","volume":"327","author":"M Guglieri","year":"2022","unstructured":"Guglieri, M. et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: A randomized clinical trial. Jama 327, 1456\u20131468 (2022).","journal-title":"Jama"},{"key":"79024_CR4","doi-asserted-by":"crossref","unstructured":"Schara, U., Mortier & Mortier, W. Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects. J. Clin. Neuromuscul. Dis. 2, 179\u2013183 (2001).","DOI":"10.1097\/00131402-200106000-00002"},{"key":"79024_CR5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1542\/peds.2018-0333F","volume":"142","author":"DR Weber","year":"2018","unstructured":"Weber, D. R., Hadjiyannakis, S., McMillan, H. J., Noritz, G. & Ward, L. M. Obesity and endocrine management of the patient with Duchenne muscular dystrophy. Pediatrics 142, S43-s52 (2018).","journal-title":"Pediatrics"},{"key":"79024_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","volume":"77","author":"DM Escolar","year":"2011","unstructured":"Escolar, D. M. et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77, 444\u2013452 (2011).","journal-title":"Neurology"},{"key":"79024_CR7","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1172\/JCI91445","volume":"127","author":"M Quattrocelli","year":"2017","unstructured":"Quattrocelli, M. et al. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. J. Clin. Invest. 127, 2418\u20132432 (2017).","journal-title":"J. Clin. Invest."},{"key":"79024_CR8","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1016\/j.ajpath.2017.07.017","volume":"187","author":"M Quattrocelli","year":"2017","unstructured":"Quattrocelli, M. et al. Intermittent glucocorticoid dosing improves muscle repair and function in mice with limb-girdle muscular dystrophy. Am. J. Pathol. 187, 2520\u20132535 (2017).","journal-title":"Am. J. Pathol."},{"key":"79024_CR9","doi-asserted-by":"crossref","unstructured":"Quattrocelli, M. et al. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight 4, (2019).","DOI":"10.1172\/jci.insight.132402"},{"key":"79024_CR10","doi-asserted-by":"publisher","first-page":"101528","DOI":"10.1016\/j.molmet.2022.101528","volume":"62","author":"M Wintzinger","year":"2022","unstructured":"Wintzinger, M. et al. Impact of circadian time of dosing on cardiomyocyte-autonomous effects of glucocorticoids. Mol. Metab. 62, 101528 (2022).","journal-title":"Mol. Metab."},{"key":"79024_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JND-210741","volume":"9","author":"AS Zelikovich","year":"2022","unstructured":"Zelikovich, A. S., Joslin, B. C., Casey, P., McNally, E. M. & Ajroud-Driss, S. An open label exploratory clinical trial evaluating safety and tolerability of once-weekly prednisone in becker and limb-girdle muscular dystrophy. J. Neuromuscul. Dis. 9, 275\u2013287 (2022).","journal-title":"J. Neuromuscul. Dis."},{"key":"79024_CR12","doi-asserted-by":"publisher","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","volume":"9","author":"Y Hathout","year":"2019","unstructured":"Hathout, Y. et al. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy. Sci. Rep. 9, 12167 (2019).","journal-title":"Sci. Rep."},{"key":"79024_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4869","volume":"36","author":"RB Khattri","year":"2023","unstructured":"Khattri, R. B. et al. Magnetic resonance quantification of skeletal muscle lipid infiltration in a humanized mouse model of Duchenne muscular dystrophy. NMR Biomed. 36, e4869 (2023).","journal-title":"NMR Biomed."},{"key":"79024_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/psp4.13021","volume":"12","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT Pharmacometrics Syst. Pharmacol. 12, 1437\u20131449 (2023).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"79024_CR15","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1212\/WNL.0000000000009012","volume":"94","author":"AM Barnard","year":"2020","unstructured":"Barnard, A. M. et al. Mr biomarkers predict clinical function in Duchenne muscular dystrophy. Neurology 94, e897\u2013e909 (2020).","journal-title":"Neurology"},{"key":"79024_CR16","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1212\/WNL.0000000000009244","volume":"94","author":"WD Rooney","year":"2020","unstructured":"Rooney, W. D. et al. Modeling disease trajectory in Duchenne muscular dystrophy. Neurology 94, e1622\u2013e1633 (2020).","journal-title":"Neurology"},{"key":"79024_CR17","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1073\/pnas.1507719112","volume":"112","author":"Y Hathout","year":"2015","unstructured":"Hathout, Y. et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 112, 7153\u20137158 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"79024_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1148\/radiol.13121948","volume":"269","author":"SC Forbes","year":"2013","unstructured":"Forbes, S. C. et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: Validation of multicenter study of evaluation with Mr imaging and Mr spectroscopy. Radiology 269, 198\u2013207 (2013).","journal-title":"Radiology"},{"key":"79024_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106435","volume":"9","author":"SC Forbes","year":"2014","unstructured":"Forbes, S. C. et al. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: A multicenter cross sectional study. PLoS ONE 9, e106435 (2014).","journal-title":"PLoS ONE"},{"key":"79024_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","volume":"24","author":"RJ Willcocks","year":"2014","unstructured":"Willcocks, R. J. et al. Longitudinal measurements of mri-T2 in boys with Duchenne muscular dystrophy: Effects of age and disease progression. Neuromuscul. Disord. 24, 393\u2013401 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"79024_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.24599","volume":"79","author":"RJ Willcocks","year":"2016","unstructured":"Willcocks, R. J. et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort. Ann.Neurol. 79, 535\u2013547 (2016).","journal-title":"Ann.Neurol."},{"key":"79024_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mrm.24917","volume":"72","author":"WT Triplett","year":"2014","unstructured":"Triplett, W. T. et al. Chemical shift-based mri to measure fat fractions in dystrophic skeletal muscle. Magn. Reson. Med. 72, 8\u201319 (2014).","journal-title":"Magn. Reson. Med."},{"key":"79024_CR23","doi-asserted-by":"crossref","unstructured":"Forbes, S. C. et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: Validation of multicenter study of evaluation with Mr imaging and Mr spectroscopy. Radiology, 121948, (2013).","DOI":"10.1148\/radiol.13121948"},{"key":"79024_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12859-016-1323-z","volume":"17","author":"GE Hoffman","year":"2016","unstructured":"Hoffman, G. E. & Schadt, E. E. Variancepartition: Interpreting drivers of variation in complex gene expression studies. BMC Bioinform. 17, 483 (2016).","journal-title":"BMC Bioinform."},{"key":"79024_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194225","volume":"13","author":"S Parolo","year":"2018","unstructured":"Parolo, S. et al. Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in Duchenne muscular dystrophy. PLoS ONE 13, e0194225 (2018).","journal-title":"PLoS ONE"},{"key":"79024_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14789450.2020.1732214","volume":"17","author":"P Dowling","year":"2020","unstructured":"Dowling, P., Gargan, S., Zweyer, M., Swandulla, D. & Ohlendieck, K. Proteomic profiling of fatty acid binding proteins in muscular dystrophy. Expert Rev. Proteom. 17, 137\u2013148 (2020).","journal-title":"Expert Rev. Proteom."},{"key":"79024_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JND-140066","volume":"2","author":"PM Burch","year":"2015","unstructured":"Burch, P. M. et al. Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. J. Neuromuscul. Dis. 2, 241\u2013255 (2015).","journal-title":"J. Neuromuscul. Dis."},{"key":"79024_CR28","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1038\/s41467-020-19489-z","volume":"11","author":"S Rodr\u00edguez-Fdez","year":"2020","unstructured":"Rodr\u00edguez-Fdez, S. et al. Vav2 catalysis-dependent pathways contribute to skeletal muscle growth and metabolic homeostasis. Nat. Commun. 11, 5808 (2020).","journal-title":"Nat. Commun."},{"key":"79024_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1177\/002215540104900807","volume":"49","author":"RA Collins","year":"2001","unstructured":"Collins, R. A. & Grounds, M. D. The role of tumor necrosis factor-alpha (Tnf-Alpha) in skeletal muscle regeneration. Studies in Tnf-Alpha(-\/-) and Tnf-Alpha(-\/-)\/Lt-Alpha(-\/-) mice. J. Histochem. Cytochem. 49, 989\u20131001 (2001).","journal-title":"J. Histochem. Cytochem."},{"key":"79024_CR30","doi-asserted-by":"publisher","first-page":"C1183","DOI":"10.1152\/ajpcell.00568.2007","volume":"294","author":"M Cheng","year":"2008","unstructured":"Cheng, M., Nguyen, M. H., Fantuzzi, G. & Koh, T. J. Endogenous interferon-gamma is required for efficient skeletal muscle regeneration. Am. J. Physiol. Cell Physiol. 294, C1183-1191 (2008).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"79024_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jbmr.1488","volume":"27","author":"M Rauner","year":"2012","unstructured":"Rauner, M. et al. Wnt5a is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J. Bone Miner. Res. 27, 575\u2013585 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"79024_CR32","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1182\/bloodadvances.2017006163","volume":"1","author":"M Gatica-Andrades","year":"2017","unstructured":"Gatica-Andrades, M. et al. Wnt ligands contribute to the immune response during septic shock and amplify endotoxemia-driven inflammation in mice. Blood Adv. 1, 1274\u20131286 (2017).","journal-title":"Blood Adv."},{"key":"79024_CR33","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/hmg\/ddaa132","volume":"29","author":"UJ Dang","year":"2020","unstructured":"Dang, U. J. et al. Serum biomarkers associated with baseline clinical severity in young Steroid-Na\u00efve Duchenne muscular dystrophy boys. Hum. Mol. Genet. 29, 2481\u20132495 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"79024_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.nmd.2016.04.012","volume":"26","author":"LM Petek","year":"2016","unstructured":"Petek, L. M. et al. A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (Fshd). Neuromuscul. Disord. 26, 405\u2013413 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"79024_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JND-210776","volume":"9","author":"WD Biggar","year":"2022","unstructured":"Biggar, W. D., Skalsky, A. & McDonald, C. M. Comparing deflazacort and prednisone in Duchenne muscular dystrophy. J. Neuromuscul. Dis. 9, 463\u2013476 (2022).","journal-title":"J. Neuromuscul. Dis."},{"key":"79024_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","volume":"102","author":"UJ Dang","year":"2024","unstructured":"Dang, U. J. et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: A randomized controlled trial. Neurology 102, e208112 (2024).","journal-title":"Neurology"},{"key":"79024_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri, M. et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: A randomized clinical trial. JAMA Neurol 79, 1005\u20131014 (2022).","journal-title":"JAMA Neurol"},{"key":"79024_CR38","doi-asserted-by":"crossref","unstructured":"Quattrocelli, M. et al. Intermittent prednisone treatment in mice promotes exercise tolerance in obesity through adiponectin. J. Exp. Med. 219, (2022).","DOI":"10.1084\/jem.20211906"},{"key":"79024_CR39","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1038\/s41598-019-42203-z","volume":"9","author":"AS Zelikovich","year":"2019","unstructured":"Zelikovich, A. S., Quattrocelli, M., Salamone, I. M., Kuntz, N. L. & McNally, E. M. Moderate exercise improves function and increases adiponectin in the Mdx mouse model of muscular dystrophy. Sci. Rep. 9, 5770 (2019).","journal-title":"Sci. Rep."},{"key":"79024_CR40","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10875-013-9867-4","volume":"33","author":"MR Pranzatelli","year":"2013","unstructured":"Pranzatelli, M. R., Tate, E. D., McGee, N. R., Colliver, J. A. & Ransohoff, R. M. Ccr4 agonists Ccl22 and Ccl17 are elevated in pediatric Oms sera: Rapid and selective down-regulation of Ccl22 by Acth or corticosteroids. J. Clin. Immunol. 33, 817\u2013825 (2013).","journal-title":"J. Clin. Immunol."},{"key":"79024_CR41","doi-asserted-by":"publisher","first-page":"1261034","DOI":"10.3389\/fped.2023.1261034","volume":"11","author":"P Zhaoyang","year":"2023","unstructured":"Zhaoyang, P. et al. Ccl22 and leptin associated with steroid resistance in childhood idiopathic nephrotic syndrome. Front. Pediatr. 11, 1261034 (2023).","journal-title":"Front. Pediatr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79024-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:08:31Z","timestamp":1732082911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79024-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79024"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79024-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.14.24308858","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EMM has been a consultant to Amgen, AstraZeneca, Cytokinetics, Pfizer, Tenaya Therapeutics, and is a founder of Ikaika Therapeutics. ARD is CSO of Ikaika Therapeutics. The other authors have declared that no conflict of interest exists. There are no nonfinancial conflicts to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28745"}}